Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2009
11/05/2009US20090275518 G-csf polypeptides and uses thereof
11/05/2009US20090275517 G-csf polypeptides and uses thereof
11/05/2009US20090275503 Diastereomeric peptides for modulating t cell immunity
11/05/2009US20090275501 Somatostatin-dopamine chimeric analogs
11/05/2009US20090275496 Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
11/05/2009US20090275082 Mast Cell-Derived Membrane Proteins
11/05/2009US20090274763 Immunoadjuvant
11/05/2009US20090274716 Lage-1 tumor associated nucleic acids
11/05/2009US20090274714 Tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
11/05/2009US20090274711 LEVELS OF BLyS/APRIL HETEROTRIMERS IN SERUM AND USE IN DIAGNOSTIC METHODS
11/05/2009US20090274707 Anti-IL-12 Antibodies, Nucleic Acids Encoding Antibodies, and Methods of Production
11/05/2009US20090274699 Ul16 binding protein 4
11/05/2009US20090274688 Antibodies to OPGL
11/05/2009US20090274680 Human Phospholipases
11/05/2009US20090274656 Hepatitis c virus inhibitors
11/05/2009US20090274653 Interleukin-2 mutants with reduced toxicity
11/05/2009US20090274649 Bispecific Antibody Point Mutations for Enhancing Rate of Clearance
11/05/2009US20090274647 Immunotherapeutic Formulations with Interleukin-2-Neutralizing Capacity
11/05/2009CA2723449A1 Methods and compositions for modulating angiogenesis and pericyte composition
11/05/2009CA2722816A1 Compositions for treating an arthritic condition
11/05/2009CA2720908A1 Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules
11/05/2009CA2720647A1 Levels of april in serum and use in diagnostic methods
11/04/2009EP2113560A1 Compositions for treating an arthritic condition
11/04/2009EP2113516A1 Antibodies against C5 inhibiting type II endothelial cell activation
11/04/2009EP2113509A2 Modulation of the expression of STAT-1 dependent genes
11/04/2009EP1979345B1 Novel pyridine derivatives
11/04/2009EP1817296B1 Potentiators of glutamate receptors
11/04/2009EP1617806B1 Selective spirocyclic glucocorticoid receptor modulators
11/04/2009EP1532130B1 Process for the production of an immunosuppressant
11/04/2009EP1481077B1 Mitotic kinesin inhibitors
11/04/2009EP1432700B1 Spiro-hydantoin compounds useful as anti-inflammatory agents
11/04/2009EP1311488B1 Substituted imidazoles as tafia inhibitors
11/04/2009EP1303488B1 Piperidine compounds for use as ccr-3 inhibitors
11/04/2009EP1204430B1 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/04/2009EP1098910B1 Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders
11/03/2009US7612238 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases
11/03/2009US7612182 Anti-IL-6 antibodies, compositions, methods and uses
11/03/2009US7612110 Immunosuppressants; for use in transplantation medicine or treatment of autoimmune diseases such as polyarthritis but not psoriatitc arthritis; micro-tablets, pellets
11/03/2009US7612095 Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid
11/03/2009US7612083 Urea substituted imidazoquinoline ethers
11/03/2009US7612047 Degradation-resistant mononucleoside phosphate compounds
11/03/2009US7612044 biodrug contains an immunogenic peptide; encoded from an isolated host cell transfected with the recombinant expression vector; diagnosis of skin cancer; vaccine for prevention and treatment; immunotherapy
11/03/2009US7612034 Administering calcitonin and dehydroepiandrosterone (DHEA) to patient being treated for systemic lupus erythematosus where the immunosuppressant tends to reduce bone mineral density(BMD); osteoporosis
11/03/2009US7611729 Dosage forms having prolonged active ingredient release
11/03/2009US7611721 Adjuvant combination formulations
11/03/2009US7611708 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
11/03/2009CA2447924C Olopatadine formulations for topical administration
11/03/2009CA2418961C Anti-il-12 antibodies, compositions, methods and uses
11/03/2009CA2383220C Controlled release pellet formulation
11/03/2009CA2205379C Yeast-based delivery vehicles
11/03/2009CA2181548C Zinc finger protein derivatives and methods therefor
10/2009
10/29/2009WO2009132130A2 Methods of identifying anti-inflammatory compounds
10/29/2009WO2009131730A2 IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
10/29/2009WO2009131604A2 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
10/29/2009WO2009131208A1 Novel lactic acid bacterium having anti-allergic activity, anti-allergic agent, food and pharmaceutical composition each comprising the lactic acid bacterium, and process for production of the anti-allergic agent
10/29/2009WO2009131171A1 Novel five-membered ring compound
10/29/2009WO2009131170A1 Five-membered ring compound
10/29/2009WO2009131098A1 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components
10/29/2009WO2009131090A1 Amino acid compound
10/29/2009WO2009130615A2 Use of deuterium oxide as an elastase inhibitor
10/29/2009WO2009130434A1 INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE
10/29/2009WO2009129616A1 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
10/29/2009WO2009106975A3 Activation of innate and adaptive immune responses by a ginseng extract
10/29/2009WO2009102465A3 Continuous cell programming devices
10/29/2009WO2009082624A3 Antagonists of il-17a, il-17f, and il-23 and methods of using the same
10/29/2009WO2009048934A3 Probiotics for use in relieving symptoms associated with gastrointestinal disorders
10/29/2009WO2009046856A3 Use of serorphin as a therapeutic agent
10/29/2009WO2009046824A3 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
10/29/2009WO2009043505A3 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
10/29/2009WO2009043504A3 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer
10/29/2009WO2009040089A3 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
10/29/2009WO2009039996A3 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent
10/29/2009WO2009039977A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection
10/29/2009WO2009033781A3 Use of k237 as therapeutic agent
10/29/2009WO2009033751A3 Use of leu-enkephalin as a therapeutic agent
10/29/2009WO2009033718A3 Use of anti -inflammatory peptide 1 as a therapeutic agent
10/29/2009WO2007146602A8 Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
10/29/2009US20090271881 Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
10/29/2009US20090270592 Purified TNFR preparations
10/29/2009US20090270492 Bryostatin analogues, synthetic methods and uses
10/29/2009US20090270458 Method of treating of demyelinating diseases or conditions
10/29/2009US20090270444 1,7-Naphthyridines
10/29/2009US20090270441 Macrolides
10/29/2009US20090270399 Novel pyridazine derivatives and medicines containing the same as effective ingredients
10/29/2009US20090270388 Fused azole-pyrimidine derivatives
10/29/2009US20090270376 Heterocyclic janus kinase 3 inhibitors
10/29/2009US20090270366 Benzoimidazole compounds
10/29/2009US20090270355 Compounds
10/29/2009US20090270347 Methods of producing microparticles
10/29/2009US20090270342 Immunoregulatory agent
10/29/2009US20090270324 Complement depletion using recombinant human c-3 derivatives
10/29/2009US20090269840 Kinase insert domain-containing receptor (KDR) specific immunoglobulin for monitoring tumor angiogenesis
10/29/2009US20090269421 Coating material
10/29/2009US20090269415 Novel therapeutic agent derived from marine organism
10/29/2009US20090269393 Chewable Bilayer Tablet Formulation
10/29/2009US20090269368 Pseudomonas exotoxin a-like chimeric immunogens
10/29/2009US20090269363 Method for screening peptides for use in immunotherapy
10/29/2009US20090269349 Antigenic polypeptides
10/29/2009US20090269338 Humanized anti-factor d antibodies and uses thereof
10/29/2009US20090269337 Compositions and methods for treating diabetes
1 ... 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 ... 1172